

Supplemental Appendix


Figure S1. Plasma triglycerides (a) and free fatty-acids (b) were measured from GcgR^{-/-} and GcgR^{+/+} PANIC ATTAC mice shown in Figure 1(a-d). Plasma insulin (c) and c-peptide (d) were measured from GcgR mAb or IgG treated mice 10 days after dimerizer treatment from Figure 1(e-g). Glucose tolerance (e) was assessed 24 days after dimerizer treatment, and plasma insulin (f) was measured 15 minutes before or after oral glucose. N=6/group.

Figure S2. Glucagon levels were measured by ELISA from plasma obtained (a) during the course of PANIC ATTAC mouse treatment with GcgR mAb or IgG control or in the absence of concurrent treatment with antibodies (b).



Figure S3. Body weight (a) and body fat mass (b) were measured in NOD mice following 4 weeks of treatment with GcgR mAb or IgG control. Free fatty-acids (c), ketone bodies (d), and ALT were measured from plasma collected after 4 weeks of treatment with GcgR mAb or IgG. N for each group are indicated.

Figure S4. Upon dissection of mice shown in Figure 5, pancreas mass was recorded (a) and total pancreatic insulin content was measured (b). Human insulin content was measured from human islet xenografts (c). Serum amino acids (d) were measured in GcgR mAb or IgG treated NOD-SCID-RIP^{DTR} mice.


Supplemental Figure 1



Supplemental Figure 2



Supplemental Figure 3



Supplemental Figure 4

